Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu L, Nimmagadda S, Sudini K, Brimacombe KR, Gajghate S, Ma J, Wang A, Xu X, Shahane SA, Xia M, Woo J, Mensah GA, Wang Z, Ferrer M, Gabrielson E, Li Z, Rastinejad F, Shen M, Boxer MB, Biswal S. Singh A, et al. Among authors: nimmagadda s. ACS Chem Biol. 2016 Nov 18;11(11):3214-3225. doi: 10.1021/acschembio.6b00651. Epub 2016 Oct 17. ACS Chem Biol. 2016. PMID: 27552339 Free PMC article.
Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S. Kumar D, et al. Among authors: nimmagadda s. J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7. J Clin Invest. 2019. PMID: 30457978 Free PMC article.
Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.
Kumar D, Mishra A, Lisok A, Kureshi R, Shelake S, Plyku D, Sen R, Doucet M, De Silva RA, Mease RC, Forde PM, Jaffee EM, Desai P, Ganguly S, Gabrielson E, Vaidya D, Spangler JB, Nimmagadda S. Kumar D, et al. Among authors: nimmagadda s. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):e2107982118. doi: 10.1073/pnas.2107982118. Proc Natl Acad Sci U S A. 2021. PMID: 34508005 Free PMC article.
Gallium-68-labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics.
Mishra A, Kumar D, Gupta K, Lofland G, Sharma AK, Banka DS, Hobbs RF, Dannals RF, Rowe SP, Gabrielson E, Nimmagadda S. Mishra A, et al. Among authors: nimmagadda s. Clin Cancer Res. 2023 Feb 1;29(3):581-591. doi: 10.1158/1078-0432.CCR-22-1931. Clin Cancer Res. 2023. PMID: 36449662 Free PMC article.
PSMA-targeted theranostic nanoplex for prostate cancer therapy.
Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG, Bhujwalla ZM. Chen Z, et al. Among authors: nimmagadda s. ACS Nano. 2012 Sep 25;6(9):7752-7762. doi: 10.1021/nn301725w. Epub 2012 Aug 9. ACS Nano. 2012. PMID: 22866897 Free PMC article.
210 results